Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 17;8(4):ofaa656.
doi: 10.1093/ofid/ofaa656. eCollection 2021 Apr.

Candida Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes

Affiliations

Candida Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes

Suheyla S Senger et al. Open Forum Infect Dis. .

Abstract

Background: Candida empyema thoracis (pleural empyema) is an uncommon manifestation of invasive candidiasis, for which optimal treatment is unknown.

Methods: This is a retrospective study of patients with Candida empyema at 2 academic medical centers from September 2006 through December 2015.

Results: We identified 81 patients with Candida empyema (median age, 62 years; 68% men). Sixty-five percent of patients underwent surgery or an invasive intervention of the thorax or abdomen within the preceding 90 days. Candida empyema originated from intrathoracic (51%) or intra-abdominal sources (20%), spontaneous esophageal rupture (12%), pleural space manipulation (9%), and pneumonia (6%). Eighty-four percent and 41% of patients were intensive care unit residents and in septic shock, respectively, within 3 days of diagnosis. Causative species were Candida albicans (65%), Candida glabrata (26%), Candida parapsilosis (11%), Candida tropicalis (4%), Candida krusei (2%), and Candida dubliniensis (1%). Bacteria were recovered from empyemas in 51% of patients. Concurrent candidemia was diagnosed in only 2% of patients. Management included pleural drainage and antifungal treatment in 98% and 85% of patients, respectively. Mortality at 100 days was 27%, and it was highest for cases stemming from esophageal rupture (67%). Spontaneous esophageal rupture and echinocandin rather than fluconazole treatment were independent risk factors for death at 100 days (P = .003 and .04, respectively); receipt of antifungal therapy was an independent predictor of survival (P = .046).

Conclusions: Candida empyema mortality rates were lower than reported previously. Optimal management included pleural drainage and fluconazole treatment. Superiority of fluconazole over echinocandins against Candida empyema needs to be confirmed in future studies.

Keywords: Candida; azole antifungal; candidiasis; echinocandin; empyema.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Sources of Candida empyema. Most cases of Candida empyema stemmed from an intrathoracic source or diaphragmatic translocation from an intra-abdominal source. Details of intrathoracic and abdominal sources are summarized in the Table 3 below.
Figure 2.
Figure 2.
Mortality of Candida empyema stratified by source of infection. GI, gastrointestinal.

References

    1. Lin KH, Liu YM, Lin PC, et al. Report of a 63-case series of Candida empyema thoracis: 9-year experience of two medical centers in central Taiwan. J Microbiol Immunol Infect 2014; 47:36–41. - PubMed
    1. Nigo M, Vial MR, Munita JM, et al. Fungal empyema thoracis in cancer patients. J Infect 2016; 72:615–21. - PubMed
    1. Ko SC, Chen KY, Hsueh PR, et al. Fungal empyema thoracis: an emerging clinical entity. Chest 2000; 117:1672–8. - PubMed
    1. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1–50. - PMC - PubMed
    1. Moriyama B, Ditullio M, Wilson E, et al. Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema. Antimicrob Agents Chemother 2011; 55:2478–80. - PMC - PubMed